A B Einstein Jr
Overview
Explore the profile of A B Einstein Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reintgen D, Albertini J, Milliotes G, Marshburn J, Cruse C, Rapaport D, et al.
J Fla Med Assoc
. 1997 Mar;
84(3):175-81.
PMID: 9143169
Objective: To perform a cost analysis of the emerging technology of lymphatic mapping for patients with malignant melanoma. Design: A retrospective, computer-aided chart and financial cost and charge review of...
2.
Einstein Jr A, Wolf M, Halliday K, Miller G, Hafermann M, Lowe B, et al.
Urology
. 1996 May;
47(5):652-7.
PMID: 8650861
Objectives: Primarily to evaluate the toxicity and, secondarily, the tumor response and patient survival associated with a three-phase combined modality treatment plan for patients with invasive transitional cell carcinoma (TCC)...
3.
Bukowski R, Tangen C, Lee R, Macdonald J, Einstein Jr A, Peterson R, et al.
J Clin Oncol
. 1992 Dec;
10(12):1914-8.
PMID: 1333517
Purpose: A phase II trial that used fluorouracil (5-FU) and chlorozotocin (CTZ) was performed in patients with metastatic islet cell carcinoma to determine the response rate and toxicity. Patients And...
4.
Oishi N, Fleming T, Laufman L, Ungerleider J, Natale R, Einstein Jr A, et al.
Invest New Drugs
. 1990 Feb;
8(1):93-5.
PMID: 2188930
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with...
5.
Einstein Jr A
NCI Monogr
. 1988 Jan;
(7):171-4.
PMID: 3050536
A patient with locally advanced prostate cancer (stages C and D1) has a poor prognosis with a high risk of developing and dying of distant metastases. Hormonal therapy is the...
6.
Shipley W, Coombs L, Einstein Jr A, Soloway M, Wajsman Z, Prout Jr G
J Urol
. 1984 Nov;
132(5):899-903.
PMID: 6436510
Twenty-seven patients with invasive bladder carcinoma (clinical stages T2 to T4) who were not candidates for cystectomy were treated by transurethral resection, cis-diamminedichloroplatinum (cisplatin) and full dose radiotherapy according to...
7.
Einstein Jr A, Shipley W, Coombs J, Cummings K, Soloway M, Hawkins I
Urology
. 1984 Apr;
23(4 Suppl):110-7.
PMID: 6538712
No abstract available.
8.
Harrison D, Neiman P, Sullivan K, Hafermann M, Rudolph R, Einstein Jr A
Cancer
. 1978 Oct;
42(4):1697-704.
PMID: 361208
Forty-six previously untreated patients with advanced aggressive non-Hodgkin's (34 poorly differentiated and mixed diffuse, 8 histiocytic and 4 undifferentiated) were treated with a 3 phase combined modality program employing cyclophosphamide...
9.
Cheever M, Einstein Jr A, Kempf R, Fefer A
Transplantation
. 1977 Apr;
23(4):299-302.
PMID: 17180
The effect of the tritiated thymidine (3H-TdR) suicide technique on the ability of donor cells to induce fatal graft-versus-host disease (GVHD) was studied. C57BL/6 (H-2b) spleen cells were stimulated in...
10.
Einstein Jr A, Cheever M, Fefer A
Transplantation
. 1976 Dec;
22(6):589-94.
PMID: 12600
The aim of our study was to sensitize cells in vitro, follow their proliferative and cytotoxic responses, and determine their ability to cause lethal graft-versus-host disease (GVHD). C57BL/6 (H2b) spleen...